Ravi Goyal received his Ph.D. in pharmacology from the University of Mississippi and MD from Armed Forces Medical College, India. He completed his post-doctoral fellowshiat Loma Linda University. Dr. Goyal joined the University of Arizona as an Associate Professor in the School of Animal and Comparative Biomedical Sciences and Bio5 Research Institute in 2018. He was also inducted as a member of University Arizona Cancer Center. Previously, he worked at the Department of Basic Sciences, School of Medicine, Loma Linda University as an Associate Professor from 2016-2018, Assistant Professor from 2009 to 2016, and Postdoctoral Research Associate from 2008-2009. He has served on several review panels of National Institute of Health, American Heart Association, and Switzerland National Science Foundation. He also serves on the editorial board of Biomed Central and Frontiers in Science Journals. His research has been funded by the National Institute of Child Health and Disease and National Heart, Lung, and Blood Institute. Dr. Goyal has taught Evidence-Based Medicine, Neuroscience, Pharmacology, Physiology, Advanced Bioinformatics, and Advanced Biotechnology Research and Methods courses from last 15 years. He has expertise in epigenetic programming of vascular function and development, stem cell differentiation, and development of targeted cancer therapy. Other projects included the development of gene therapy to convert adipose-derived stem cells in insulin-secreting cells as well as developing a suicide gene therapy to target cancer cells. The major approaches the grouuse to investigate angiogenesis, stem cell differentiation, and development of targeted cancer therapeutics are aimed at the identification of the novel transcripts including long non-coding RNA involved in these processes. These transcriptomic regions are then examined with contemporary bioinformatic methods to identify conserved regions in the mouse, sheep, and human genome. Following identification of the conserved region, we use the CRISPR technique to knockdown or activate these regions to determine their functional implications. We hope to identify molecular targets by which we can increase or decrease angiogenesis, improve stem cells differentiation efficiency and provide a targeted approach to kill cancer cells. The significant contribution of Goyal’s grouis providing evidence that balanced nutrition and optimal oxygenation is vital for a healthier life of the offspring and prevention of diseases in adult life. Specifically, the grouhas demonstrated that despite adequate calories, protein malnutrition during pregnancy can lead to lifelong consequences in the offspring. Furthermore, they have shown that this programming occurs at the epigenetic level and can be inheritable. Other contributions include hypoxia-mediated alterations of gene expression in arterial contractility and angiogenesis. Currently, the grouis investigating the role of long non-coding RNA on angiogenesis and vascular development. Dr. Goyal’s lab grouhas published several peer-reviewed original research articles, reviews, and book chapters on cardiovascular and cerebrovascular changes in response to maternal stress.